ANALYST CALL: Coming to America: Sandoz Files the First Biosimilar in the United States

launch Related Market Assessment Reports

• Biosimilars – Market Events And Forecast – Overview Of Biosimilars Forecasts

  March 2023

  In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…

• Biosimilars – Market Events And Forecast – Immunology

  In 2021, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…

• Biosimilars – Market Events And Forecast – Respiratory

  In 2021, sales of branded biologics for respiratory indications reached nearly $0.7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031…

• Biosimilars – Market Events And Forecast – Endocrinology

  In 2021, sales of insulins at the ex-manufacturer price level exceeded $16 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031 forecast…

• Biosimilars – Market Events And Forecast – Nephrology

  In 2021, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled almost $2.5 billion in the major pharmaceutical markets under study (…